CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 52 enrolled
Drug / intervention
AAB-003 (PF-05236812) +4 moredrug
Likely dose
AAB-003 (PF-05236812) 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01369225
NCT01369225Phase 1Completed
CompareCT.gov

A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001

Pfizer·interventional·Posted Jun 8, 2011·Updated Mar 10, 2017

In Brief

A Phase 1 clinical trial evaluating AAB-003 (PF-05236812) for Alzheimer's Disease. Completed, enrolled 52 participants across 21 sites in 2 countries.

Detailed Summary

This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesSouth Korea, United States
CollaboratorsJANSSEN Alzheimer Immunotherapy Research & Development, LLC

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 8, 2011
Enrollment StartJul 1, 2011
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.1 years ago

Interventions

AAB-003 (PF-05236812)drug

0.5 mg/kg AAB-003, IV

AAB-003 (PF-05236812)drug

1 mg/kg AAB-003, IV

AAB-003 (PF-05236812)drug

2 mg/kg AAB-003, IV

AAB-003 (PF-05236812)drug

4 mg/kg AAB-003, IV

AAB-003 (PF-05236812)drug

8 mg/kg AAB-003, IV